Product
C5252
1 clinical trial
4 indications
Indication
Solid TumorIndication
GlioblastomaIndication
Glioblastoma MultiformeIndication
Glioblastoma Multiforme of BrainClinical trial
A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive GlioblastomaStatus: Not yet recruiting, Estimated PCD: 2023-04-30